IRVINE, Calif., July 28, 2021 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the first patient has been dosed in the STRIDE study. The trial is designed to evaluate the efficacy and safety of… Continue reading Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study
